Traders Buy Shares of Becton, Dickinson and Company (BDX) on Weakness Following Insider Selling

Traders bought shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading on Tuesday after an insider sold shares in the company. $71.81 million flowed into the stock on the tick-up and $44.34 million flowed out of the stock on the tick-down, for a money net flow of $27.47 million into the stock. Of all equities tracked, Becton, Dickinson and had the 15th highest net in-flow for the day. Becton, Dickinson and traded down ($1.67) for the day and closed at $202.20Specifically, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,904 shares of company stock valued at $15,242,688. Corporate insiders own 1.40% of the company’s stock.

Several analysts have recently commented on BDX shares. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their target price for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $196.93.

The stock has a market capitalization of $46.01 billion, a price-to-earnings ratio of 58.56 and a beta of 1.06. The stock has a 50 day moving average of $200.08 and a 200 day moving average of $191.02.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.35 EPS. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America boosted its stake in Becton, Dickinson and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 6 shares during the period. Family Firm Inc. boosted its stake in Becton, Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC boosted its stake in Becton, Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the period. Wellington Shields & Co. LLC boosted its stake in Becton, Dickinson and by 0.3% in the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 7 shares during the period. Finally, Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares during the period. 87.43% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/09/13/traders-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness-following-insider-selling.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply